This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

NBI-5788

Neurocrine Biosciences, Inc.

Drug Names(s): MSP771, Tiplimotide

Description: NBI-5788 is an altered peptide ligand (APL) that can potentially interfere with the autoimmune response in multiple sclerosis patients.

Deal Structure: Novartis ended its partnership with Neurocrine to develop NBI-5788 in early 2000.


NBI-5788 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug